Key Points
- Director Glenn Nussdorf sold 100,000 shares at an average price of $5.34 for $534,000, reducing his stake by 3.26% to 2,965,591 shares valued at about $15.84 million.
- Organogenesis beat the quarter with EPS of $0.18 (vs. $0.07 est.) and revenue of $150.86M (vs. $134.10M), but still showed a negative net margin (-1.3%) and faces a mixed analyst picture with a consensus "Hold" and an average price target of $8.00.
- Shares opened at $5.42 (up ~2.7%), trading in a 52-week range of $2.61–$7.08 with a market cap around $688M, and roughly 49.6% of the stock is held by institutional investors amid recent sizable inflows.
Organogenesis (NASDAQ:ORGO - Get Free Report) Director Glenn Nussdorf sold 12,043 shares of the stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $5.30, for a total value of $63,827.90. Following the sale, the director owned 2,953,548 shares of the company's stock, valued at approximately $15,653,804.40. This represents a 0.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Organogenesis Stock Performance
Shares of Organogenesis stock traded up $0.14 during midday trading on Thursday, hitting $5.42. The company had a trading volume of 1,027,809 shares, compared to its average volume of 3,117,986. The company has a quick ratio of 2.88, a current ratio of 3.32 and a debt-to-equity ratio of 0.01. Organogenesis has a 12-month low of $2.61 and a 12-month high of $7.08. The stock has a market cap of $687.85 million, a price-to-earnings ratio of -45.17 and a beta of 1.68. The company has a fifty day simple moving average of $4.65 and a 200 day simple moving average of $4.28.
Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.18 EPS for the quarter, topping analysts' consensus estimates of $0.07 by $0.11. The company had revenue of $150.86 million during the quarter, compared to analysts' expectations of $134.10 million. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%. Organogenesis has set its FY 2025 guidance at EPS. As a group, analysts predict that Organogenesis will post -0.07 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the company. BTIG Research raised their target price on Organogenesis from $7.00 to $9.00 and gave the company a "buy" rating in a research report on Thursday, November 20th. Wall Street Zen raised shares of Organogenesis from a "hold" rating to a "strong-buy" rating in a research note on Saturday, November 8th. Cantor Fitzgerald upped their price objective on Organogenesis from $7.00 to $9.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Finally, Weiss Ratings reissued a "sell (d+)" rating on shares of Organogenesis in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Organogenesis presently has an average rating of "Hold" and an average price target of $8.00.
View Our Latest Research Report on ORGO
Institutional Investors Weigh In On Organogenesis
Institutional investors and hedge funds have recently modified their holdings of the company. PharVision Advisers LLC acquired a new position in Organogenesis during the third quarter worth $155,000. Quarry LP acquired a new stake in Organogenesis in the 3rd quarter valued at about $25,000. First Light Asset Management LLC raised its position in Organogenesis by 10.6% during the third quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company's stock worth $31,641,000 after acquiring an additional 720,748 shares during the last quarter. Bank of America Corp DE raised its position in shares of Organogenesis by 27.2% during the 3rd quarter. Bank of America Corp DE now owns 611,685 shares of the company's stock worth $2,581,000 after purchasing an additional 130,875 shares during the last quarter. Finally, Creative Planning lifted its stake in Organogenesis by 8.2% in the 3rd quarter. Creative Planning now owns 38,279 shares of the company's stock valued at $162,000 after buying an additional 2,887 shares in the last quarter. Institutional investors and hedge funds own 49.57% of the company's stock.
Organogenesis Company Profile
(
Get Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
